RSS
Логотип
Баннер в шапке 1
Баннер в шапке 2

Eroxo (gel for improving male potency)

Product
Developers: Futura Medical
Date of the premiere of the system: July 2023
Branches: Pharmaceuticals, Medicine, Healthcare

2023: Gel Announcement

In mid-June 2023, Futura Medical announced that it is entering the market for Eroxon over-the-counter gel for the treatment of male erectile dysfunction repair. The drug has a cooling and then warming effect, fixing the problem within about 10 minutes, the manufacturer claims. This is significantly faster than when taking popular oral medicines such as Pfizer's Viagra or Eli Lilly's Cialis.

Among the advantages of Eroxon gel over pills is the lack of likely complications that can occur when drinking alcohol and some types of food before sexual intercourse, men. As of June 14, 2023, Eroxon is available in Belgium and the UK and has commercial agreements in the European Economic Area (EEA), Latin America, Switzerland, South Korea and the Middle East. The four-pack costs around $31, it's not known when Eroxon will hit the US.

Eroxo (gel for improving male potency)
File:Aquote1.png
The FDA has set a very high standard in evaluating the efficacy and safety of "de novo" medical devices. I am glad that we have met this standard! Modern technologies and methods of treating impotence with timely diagnosis make it possible to significantly improve the quality of sexual life of a man. This disorder is a recurring condition that is characterized by a violation of the quality of the erection and the inability to support or achieve it to the extent necessary for full sexual intercourse, said James Barder, CEO of Futura Medical.
File:Aquote2.png

Futura Medical claims that Eroxon gel can help users get an erection within 10 minutes of being applied to the head of the penis, and boasts success in 65% of cases. The company announced that it plans to continue to establish exports of the drug throughout 2023.

According to WHO, up to 30 million American men suffer from erectile dysfunction for 2023. Harvard Health estimates the condition affects 1% of men in their 40s, 17% of men in their 60s and nearly 50% of men 75 and older.[1]

Notes